Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)

  • Etude concernée: IFCT-0301
  • Auteurs / Authors: Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF
  • Journal / Conference: Journal of Geriatric Oncology
  • Année / Year: 2015
  • PMID: 25698450
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/25698450
  • PDF: JGO_2015_-_IFCT_0301.pdf